Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Market Closed 05-22 16:00:00 EDT

1.10

+0.03

+2.80%

盘后1.10

+0.000.00%

19:54 EDT

High1.13	Low1.04	Vol1.23M
Open1.04	D1 Closing1.07	Amplitude8.41%
Mkt Cap17.93M	Tradable Cap17.02M	Total Shares16.30M
T/O1.34M	T/O Rate7.94%	Tradable Shares15.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":1.1,"timestamp":1779480000000,"preClose":1.07,"halted":0,"volume":1229399,"hourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"19:54 EDT","volume":14597,"amount":15893.0004,"timestamp":1779494047231,"change":0,"changeRate":0,"amplitude":0.033273},"delay":0,"changeRate":0.028037383177570117,"floatShares":15475151,"shares":16300700,"eps":-9.1075,"marketStatus":"Market Closed","change":0.03,"latestTime":"05-22 16:00:00 EDT","open":1.04,"high":1.13,"low":1.04,"amount":1343572.0557310001,"amplitude":0.084112,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.1075,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":1.07,"preHourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.07,"latestTime":"09:28 EDT","volume":46273,"amount":49896.4581653,"timestamp":1779456480065,"change":-0.01,"changeRate":-0.009346,"amplitude":0.034393},"postHourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"19:54 EDT","volume":14597,"amount":15893.0004,"timestamp":1779494047231,"change":0,"changeRate":0,"amplitude":0.033273},"volumeRatio":0.2157344336853356,"impliedVol":2.224,"impliedVolPercentile":0.7297},"requestUrl":"/m/hq/s/QNCX/wiki","defaultTab":"wiki","newsList":[{"id":"2637390357","title":"Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637390357","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637390357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:07","pubTimestamp":1779397654,"startTime":"0","endTime":"0","summary":"Quince Therapeutics regained compliance with Nasdaq Global Market continued listing standards, closing a prior deficiency tied to the minimum market value of listed securities requirement.Nasdaq had issued a notice on March 17, 2026, citing failure to maintain a $50 million minimum market value of listed securities over 30 consecutive business days under Listing Rule 5450.A May 20, 2026 letter from Nasdaq said the company now meets Listing Rule 5450 based on stockholders’ equity of $15.67 million reported in its quarterly filing for the period ended March 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLbckKxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636792820","title":"Quince Therapeutics announces LAM-001 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2636792820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636792820?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:41","pubTimestamp":1779111664,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin, in patients with pulmonary arterial hyp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-announces-lam-001-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-announces-lam-001-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4007","BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636498079","title":"Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2636498079","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636498079?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:35","pubTimestamp":1779111306,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (QNCX) announced it has acquired Orphai Therapeutics. The acquisition brings Orphai’s program LAM-001, an inhaled formulation o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-acquires-orphai-therapeutics-terms-undisclosed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-acquires-orphai-therapeutics-terms-undisclosed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079919","title":"Quince Therapeutics prices private placement raising up to $187 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079919","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079919?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:34","pubTimestamp":1779111273,"startTime":"0","endTime":"0","summary":"Quince Therapeutics entered a private placement to raise up to USD 187 million in gross proceeds tied to an unregistered sale of Series C non-voting convertible preferred stock.The deal includes USD 115 million of upfront proceeds, with up to about USD 72 million more available from warrant exercises.Balyasny Asset Management led the financing, with participation from several other healthcare-focused investors.Proceeds, together with cash at closing, are expected to fund operations through end-2028, supporting LAM-001 development with Phase 2 BOS data targeted for Q1 2027 and Phase 2b PH-ILD data targeted for Q1 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9fVMzY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079673","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079673","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079673?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:33","pubTimestamp":1779111221,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nAQN2LZF7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079392","title":"Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079392","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079392?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:27","pubTimestamp":1779110829,"startTime":"0","endTime":"0","summary":"Quince Therapeutics has acquired clinical-stage Orphai Therapeutics, adding lead asset LAM-001, an inhaled rapamycin formulation being developed for pulmonary diseases including PH-ILD and bronchiolitis obliterans syndrome.The stock-for-stock deal exchanges Orphai equity for 3,258,517 Quince common shares, 67,101 shares of Series C non-voting convertible preferred stock, options for 26,332,798 common shares, and replacement warrants that could generate about $10.9 million if exercised.A concurrent private placement is set to raise up to $187 million in gross proceeds, including $115 million upfront, with up to about $72 million tied to warrant exercise; closing is expected May 21, 2026.On a fully diluted basis assuming full conversion of the Series C preferred, pre-deal Quince holders are expected to own about 6.9%, legacy Orphai holders about 31.9%, and private placement investors about 61.2%.Cash from the financing and existing balances are expected to fund operations through end-202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1hYrfV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","QNCX","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","BK4588","BK4112","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636307936","title":"Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636307936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636307936?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:27","pubTimestamp":1779110823,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636337079","title":"Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2636337079","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636337079?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110798,"startTime":"0","endTime":"0","summary":"Quince Therapeutics reported Phase 2a results for inhaled rapamycin candidate LAM-001 in pulmonary arterial hypertension, including pulmonary hypertension tied to interstitial lung disease, with data already presented at the American Thoracic Society conference.The open-label add-on study showed clinically meaningful improvement or stabilization across exercise capacity, pulmonary blood-flow measures, cardiac-stress biomarkers, lung function, with patients also moving to a better functional class by the end of treatment.LAM-001 was generally well tolerated on top of standard of care in evaluable patients, supporting continued development in the more severe PH-ILD subgroup.A Phase 2b trial in PH-ILD is scheduled to start in mid-2026, with topline data expected in the first quarter of 2028.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLPT3ml:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","QNCX","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636793820","title":"Quince Therapeutics - Lam-001 Generally Well Tolerated in Phase 2a Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636793820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636793820?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110779,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA6XXVRH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636793380","title":"Quince Therapeutics - Lam-001 Phase 2a in Ph-Ild Shows 67.4M 6Mwd Improvement, 33.9% Pvr Reduction at 24 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636793380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636793380?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110779,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA6XXVRH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079387","title":"Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in Pah and Ph-Ild","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079387?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110779,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA6XXVRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079384","title":"Quince Therapeutics - Phase 2B Trial in Ph-Ild to Start Mid-2026, Topline Data Expected Q1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079384?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110779,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA6XXVRH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634925388","title":"Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634925388","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634925388?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:10","pubTimestamp":1778533848,"startTime":"0","endTime":"0","summary":"Quince Therapeutics swung to net income of USD 35.91 million, reflecting a USD 67.81 million intangible asset impairment charge offset by a USD 64.33 million fair-value adjustment for contingent consideration.Operating loss narrowed 2% to USD 14.59 million, as research and development expense fell 16% to USD 6.85 million; general and administrative costs dropped 11% to USD 4.27 million.Cash and cash equivalents totaled USD 18.2 million as of March 31, 2026, and the company said it expects that balance will not fund operations for the 12 months following the filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL5nys2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633373468","title":"Quince Therapeutics Inc  expected to post a loss of $2.56 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633373468","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633373468?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:30","pubTimestamp":1778254248,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc  expected to post a loss of $2.56 a share - Earnings Preview Quince Therapeutics Inc QNCX.OQ QNCX.O is expected to  show no change in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631390695","title":"Quince Therapeutics regains Nasdaq $1 minimum bid price compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631390695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631390695?lang=en_us&edition=fundamental","pubTime":"2026-04-29 05:05","pubTimestamp":1777410334,"startTime":"0","endTime":"0","summary":"Quince Therapeutics regained compliance with Nasdaq minimum bid price rule 5450 following 10 straight sessions with a closing bid at or above $1 from April 13 through April 24.Nasdaq closed bid-price deficiency matter in a letter dated April 27.Market value of listed securities deficiency under Nasdaq rule 5450 remains unresolved, with $50 million minimum required for Nasdaq Global Select Market.Company has until Sept. 14, 2026 to regain compliance with market value requirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commiss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL7PpnY5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629871073","title":"Quince Therapeutics appoints June Bray to board as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2629871073","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629871073?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:44","pubTimestamp":1776890678,"startTime":"0","endTime":"0","summary":"Quince Therapeutics expanded board to four directors on April 22, 2026.June Bray was appointed as Class I director, serving until 2026 annual stockholder meeting.Board determined Bray qualifies as an independent director under Nasdaq listing standards.Bray joined board committees covering nominating and governance, audit, compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLb5nXdD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629346200","title":"Largest borrow rate increases among liquid names","url":"https://stock-news.laohu8.com/highlight/detail?id=2629346200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629346200?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:49","pubTimestamp":1776775746,"startTime":"0","endTime":"0","summary":"Latest data shows the largest indicative borrow rate increases among liquid option names include: Quince Therapeutics (QNCX) 91.74% +3.37, Tradr 2X...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/largest-borrow-rate-increases-among-liquid-names-thefly-news-41?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/largest-borrow-rate-increases-among-liquid-names-thefly-news-41?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628827797","title":"Quince Therapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628827797","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628827797?lang=en_us&edition=fundamental","pubTime":"2026-04-18 05:26","pubTimestamp":1776461196,"startTime":"0","endTime":"0","summary":"Quince Therapeutics set June 11, 2026 for virtual annual stockholder meeting via live webcast.Key vote covers charter amendment authorizing board to implement reverse stock split within 1-for-10 to 1-for-100 range.Other items include ratification of BDO USA as independent auditor for fiscal 2026.Stockholders will also cast advisory vote on named executive officer compensation.Meeting will also seek approval to adjourn or postpone session if needed to secure votes on proposals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL8sVJZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626711841","title":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 03:28 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2626711841","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626711841?lang=en_us&edition=fundamental","pubTime":"2026-04-12 15:28","pubTimestamp":1775978916,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 03:28 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nAQN2LUBR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626460481","title":"Quince Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2626460481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626460481?lang=en_us&edition=fundamental","pubTime":"2026-04-11 07:53","pubTimestamp":1775865195,"startTime":"0","endTime":"0","summary":"19:50 EDT Quince Therapeutics (QNCX) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","QNCX","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":-0.0435},{"period":"1month","weight":-0.1971},{"period":"3month","weight":-0.2672},{"period":"6month","weight":-0.9486},{"period":"1year","weight":-0.8991},{"period":"ytd","weight":-0.9672}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.091321},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.101646},{"month":3,"riseRate":0.428571,"avgChangeRate":0.087035},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.03031},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.097806},{"month":6,"riseRate":0.714286,"avgChangeRate":0.184618},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.077216},{"month":8,"riseRate":0.428571,"avgChangeRate":0.032954},{"month":9,"riseRate":0.571429,"avgChangeRate":0.013938},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.049658},{"month":11,"riseRate":0.571429,"avgChangeRate":0.199459},{"month":12,"riseRate":0.285714,"avgChangeRate":0.079276}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}